The investment seeks to track the investment results of the S&P Target Risk Moderate Index composed of a portfolio of underlying equity and fixed income funds intended to represent a moderate target risk allocation strategy. The fund is a fund of funds and seeks its investment objective by investing... The investment seeks to track the investment results of the S&P Target Risk Moderate Index composed of a portfolio of underlying equity and fixed income funds intended to represent a moderate target risk allocation strategy. The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 90% of its assets in the component securities of the underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model. Show more
ActiveOps PLC said Thursday it has raise GBP75.7 million gross for selling shareholders in its initial public offerin ...
In these volatile times, most investors are faced with the dilemma of deciding which asset class to put their hard earned capital to work in. During times of economic uncertainties, most...
San Francisco-based iShares is the world’s largest exchange traded funds (ETFs) provider with 46% of the market share. It offers a variety of ETFs across different asset classes, sectors...
SEATTLE, Oct. 26 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the appointment of Stephen Becker, M.D., as chief medical officer. Dr. Becker joins Koronis from AnorMED...
Agreement Eliminates Development Milestones, Significantly Reduces Royalties and Restructures Sublicense Provisions SOUTH SAN FRANCISCO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Poniard...
VANCOUVER, Sept. 7 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that its common shares will begin trading on September 8, 2006 on the NASDAQ Global Market of the...
VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) announced that its Board of Directors, based on the recommendation of its Strategic...
VANCOUVER, Sept. 1 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today confirmed that Genzyme Corp. has commenced an unsolicited offer through a...
Proposed Acquisition Will Add Complementary Late-Stage Transplant Product CAMBRIDGE, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it plans to...
Considers Genzyme Proposal Undervalued VANCOUVER, Aug. 30 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today announced that its Board of Directors has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.92 | -2.05954779494 | 44.67 | 44.67 | 43.27 | 305245 | 43.81009233 | SP |
4 | -0.77 | -1.72955974843 | 44.52 | 45.1381 | 43.27 | 229863 | 44.45323223 | SP |
12 | -1.34 | -2.97183410956 | 45.09 | 45.1381 | 43.27 | 146501 | 44.39333184 | SP |
26 | 0.6 | 1.39049826188 | 43.15 | 45.31 | 42.55 | 117903 | 44.10395982 | SP |
52 | 2.44 | 5.90656015493 | 41.31 | 45.31 | 40.75 | 130224 | 42.87632693 | SP |
156 | -1.57 | -3.46425419241 | 45.32 | 45.6799 | 35.71 | 193084 | 40.56685924 | SP |
260 | 3.72 | 9.29303022733 | 40.03 | 46.045 | 33.25 | 191376 | 40.96453118 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.